1 / 8

Glioblastoma -Opportunity Analysis and Forecasts to 2024

Glioblastoma multiforme (GBM) is characterized as a disease with some of the highest unmet needs in oncology, with patients having a median overall survival (OS) of between one and two years. The lack of therapies is primarily due to the inability of drugs to penetrate the blood-brain barrier (BBB). The GBM market is currently dominated by temozolomide and Avastin which are considered as standards of care in newly diagnosed and recurrent settings, respectively

bhagyashree
Download Presentation

Glioblastoma -Opportunity Analysis and Forecasts to 2024

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Glioblastoma -Opportunity Analysis and Forecasts to 2024

  2. Opportunity Analyzer: Glioblastoma - Opportunity Analysis and Forecasts to 2024 Glioblastoma multiform (GBM) is characterized as a disease with some of the highest unmet needs in oncology, with patients having a median overall survival (OS) of between one and two years. The lack of therapies is primarily due to the inability of drugs to penetrate the blood-brain barrier (BBB). The GBM market is currently dominated by temozolomide and Avast in which are considered as standards of care in newly diagnosed and recurrent settings, respectively. Between 2014 and 2024, the market is set to undergo substantial growth due to a number companies developing therapies in the late-stage pipeline, which is dominated by immunotherapies. On one hand, the main drivers of growth will be the launch of EGFR-targeting therapies such as Rintega and ABT-414, as well as the checkpoint inhibitor Opdivo. Furthermore, the launch of autologous cell vaccines such as ICT-107 and DCVax-L will also impact the GBM market. On the other hand, the GBM market constrainers remain modest with the increasing cost-consciousness of healthcare providers, and the launch of biosimilar bevacizumab in the 7MM (US, France, Germany, Italy, Spain, UK and Japan).  +1 408 520 9750  www.absolutereports.com sales@absolutereports.com

  3. Topics Revealed in this Report The main driver of the enormous expansion of the GBM market will be the launch of Opdivo for newly diagnosed and recurrent GBM. GlobalData forecasts significant patient uptake for Opdivo which will supersede Avastin to become the SoC in the recurrent setting. Risk Factors and Comorbidities Epidemiological Forecast for Brain Cancer(2014-2024) Identification of New Treatment Options for Patients with rGBM Refractory to Avastin Physicians and Specialists Included in this Study  +1 408 520 9750  www.absolutereports.com sales@absolutereports.com

  4. Major/Key players AnalysisThe Research Provides Company Overview, Business Description, SWOT Analysis, Major Products/Services, Head Office, etc. of Following Companies: Arbor Pharmaceuticals AbbVie Bristol-Myers Squibb Company CelldexTherapeutics Fujifilm GreenPeptide ImmunocellularTherapeutics Ono Pharmaceuticals Peregrine Pharmaceuticals Pfizer  +1 408 520 9750  www.absolutereports.com sales@absolutereports.com

  5. Scope of the Report Overview of GBM, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines. Annualized GBM therapeutics market revenue, average cost of therapy and treatment usage pattern data from 2014 and forecast for ten years to 2024. Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the GBM therapeutics market. Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs. Analysis of the current and future market competition in the global GBM therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.  +1 408 520 9750  www.absolutereports.com sales@absolutereports.com

  6. Why one should buy this report? Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list. Develop business strategies by understanding the trends shaping and driving the global GBM therapeutics market. Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global GBM therapeutics market in future. Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors. Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. Track drug sales in the global GBM therapeutics market from 2014-2024.  +1 408 520 9750  www.absolutereports.com sales@absolutereports.com

  7. Report Details No. Of Pages : 206 No of Tables : 75 No. Figures : 23 Price : $9495(Single User Licence)  +1 408 520 9750  www.absolutereports.com sales@absolutereports.com

  8. Contact: Mr. AmeyaPingaley  +1 408 520 9750  www.absolutereports.com sales@absolutereports.com

More Related